First New Zealand Registration of Guideline Recommended UTI Treatment
The Prescription Medicine UroFos® (fosfomycin) has been registered by Medsafe for the treatment of acute uncomplicated urinary tract infection (UTIs) in adult women and adolescents aged over 12.
"UroFos® represents the first of a new antibiotic class in New Zealand and is registered as a single dose treatment for women experiencing a UTI. Single dose oral fosfomycin is convenient and highly effective against a broad range of UTI causing bacteria, these advantages are reflected in PHARMACs high priority recommendation for funding.” Scott Lissington COO Te Arai BioFarma.
For more information:
Te Arai BioFarma Ltd. 0800 TE ARAI.
UroFos® (Fosfomycin) is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at www.medsafe.govt.nz. UroFos® is a registered Trademark of Te Arai BioFarma Ltd, Auckland.
Te Arai BioFarma is a New Zealand owned family company created to improve access to Medicines for New Zealanders